Asthma News

ANAHEIM, Calif. — Virtual coaching improved symptoms among patients who identified as Black with very poorly controlled asthma, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

HONOLULU — Patients with well-controlled asthma who use dupilumab may tolerate a reduction in the frequency of their doses from every 2 weeks to every 4 weeks, according to a poster presented at the CHEST Annual Meeting.

Incidence rates for several respiratory viruses, including influenza and respiratory syncytial virus, declined during vs. before the COVID-19 pandemic, according to study results published in Thorax.

Intranasal corticosteroids did not impact COVID-19 mortality in patients with asthma, COPD or neither, but they did reduce the risk for all-cause mortality, according to study results published in Annals of Allergy, Asthma & Immunology.

ANAHEIM, Calif — Benralizumab lowered the rate of COPD exacerbations among patients with asthma and COPD after 1 year, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — The wildfires in Canada in May and June 2023 were associated with short-term increases in asthma reliever use, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — Unfamiliarity with biologics to treat uncontrolled asthma was reported by 42% of primary care physicians, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

ANAHEIM, Calif. — Between 1990 and 2019, asthma prevalence has risen in the U.S., according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Outcomes improved for patients with severe asthma who took mepolizumab regardless of their other comorbidities, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Income-based deductibles reduced public drug costs without any effect on medication use or adherence in patients with asthma and low incomes in British Columbia, according to a study published in Annals of Allergy, Asthma & Immunology.